Clinical and Microbiological Characteristics of Candidemia Cases in Saudi Arabia

References

• Bassetti M, Righi E, Costa A, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis. 2006;6. doi:10.1186/1471-2334-6-21
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Cases from a prospective nationwide surveillance study. BSI US Hosp CID. 2004;309:1.
   Google Scholar
• Aldardeer NF, Albar H, Al-Attas M, et al. Antifungal resistance in patients with Candidaemia: a retrospective cohort study. BMC Infect Dis. 2020;20(1). doi:10.1186/s12879-019-4710-z
   PubMed Web of Science ®Google Scholar
• Koehler P, Stecher M, Cornely OA, et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clin Microbiol Infect. 2019;25(10):1200–1212. doi:10.1016/j.cmi.2019.04.024
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Carvalhaes CG, DeVries S, Huband MD, Castanheira M. Elderly versus nonelderly patients with invasive fungal infections: species distribution and antifungal resistance, SENTRY antifungal surveillance program 2017–2019. Diagn Microbiol Infect Dis. 2022;102(4):115627. doi:10.1016/j.diagmicrobio.2021.115627
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol. 2001;39(9):3254–3259. doi:10.1128/JCM.39.9.3254-3259.2001
   PubMed Web of Science ®Google Scholar
• Akbar DH, Tahawi AT. Candidemia at a university hospital: epidemiology, risk factors and predictors of mortality. Ann Saudi Med. 2001;21(3–4):178–182. doi:10.5144/0256-4947.2001.178
   PubMed Web of Science ®Google Scholar
• Al-Jasser AM, Elkhizzi NA. Distribution of Candida species among bloodstream isolates. Saudi Med J. 2004;25(5):566–569.
   PubMed Web of Science ®Google Scholar
• Al-Hedaithy SSA. The yeast species causing fungemia at a university Hospital in Riyadh, Saudi Arabia, during a 10-year period. Mycoses. 2003;46(8):275–280. doi:10.1046/j.1439-0507.2003.00893.x
   Web of Science ®Google Scholar
• Omrani AS, Makkawy EA, Baig K, et al. Ten-year review of invasive Candida infections in a tertiary care center in Saudi Arabia. Saudi Med J. 2014;35(8):821–826.
   PubMed Web of Science ®Google Scholar
• Al-Tawfiq JA. Distribution and epidemiology of Candida species causing fungemia at a Saudi Arabian hospital, 1996–2004. Int J Infect Dis. 2007;11(3):239–244. doi:10.1016/j.ijid.2006.03.003
   PubMed Web of Science ®Google Scholar
• Al-Musawi TS, Alkhalifa WA, Alasaker NA, Rahman JU, Alnimr AM. A seven-year surveillance of Candida bloodstream infection at a university hospital in KSA. J Taibah Univ Med Sci. 2021;16(2):184–190. doi:10.1016/j.jtumed.2020.12.002
   PubMed Web of Science ®Google Scholar
• Bukharie HA. Nosocomial Candidemia in a tertiary care hospital in Saudi Arabia. Mycopathologia. 2001;153:1.
   Web of Science ®Google Scholar
• Poissy J, Damonti L, Bignon A, et al. Risk factors for candidemia: a prospective matched case-control study. Crit Care. 2020;24(1). doi:10.1186/s13054-020-2766-1
   Web of Science ®Google Scholar
• Rodríguez D, Almirante B, Cuenca-Estrella M, et al. Predictors of candidaemia caused by non-albicans Candida species: results of a population-based surveillance in Barcelona, Spain. Clin Microbiol Infect. 2010;16(11):1676–1682. doi:10.1111/j.1469-0691.2010.03208.x
   PubMed Web of Science ®Google Scholar
• Kayaaslan B, Eser F, Kaya Kalem A, et al. Characteristics of candidemia in COVID-19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non-COVID-19 patients. Mycoses. 2021;64(9):1083–1091. doi:10.1111/myc.13332
   PubMed Web of Science ®Google Scholar
• Riche CVW, Cassol R, Pasqualotto AC. Is the frequency of candidemia increasing in covid-19 patients receiving corticosteroids? J Fungus. 2020;6(4):1–4. doi:10.3390/jof6040286
   Google Scholar
• Omrani AS, Koleri J, Ben Abid F, et al. Clinical characteristics and risk factors for COVID-19-associated Candidemia. Med Mycol. 2021;59(12):1262–1266. doi:10.1093/mmy/myab056
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhu R, Luan Z, Ma X. Risk of invasive candidiasis with prolonged duration of ICU stay: a systematic review and meta-analysis. BMJ Open. 2020;10(7):e036452. doi:10.1136/bmjopen-2019-036452
   PubMed Web of Science ®Google Scholar
• Ala-Houhala M, Valkonen M, Kolho E, Friberg N, Anttila VJ. Clinical and microbiological factors associated with mortality in candidemia in adult patients 2007–2016. Infect Dis. 2019;51(11–12):824–830. doi:10.1080/23744235.2019.1662941
   PubMed Web of Science ®Google Scholar
• Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49(9):3640–3645. doi:10.1128/AAC.49.9.3640-3645.2005
   PubMed Web of Science ®Google Scholar
• Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study; 2006. Available from: https://academic.oup.com/cid/article/43/1/25/308688. Accessed June 23, 2023.
   Google Scholar
• Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother. 2010;54(1):184–190. doi:10.1128/AAC.00945-09
   PubMed Web of Science ®Google Scholar
• Nunes CZ, Marra AR, Edmond MB, da Silva Victor E, Pereira CAP. Time to blood culture positivity as a predictor of clinical outcome in patients with Candida albicans bloodstream infection. BMC Infect Dis. 2013;13(1). doi:10.1186/1471-2334-13-486
   Google Scholar
• Zhong L, Zhang S, Tang K, et al. Clinical characteristics, risk factors and outcomes of mixed Candida albicans/bacterial bloodstream infections. BMC Infect Dis. 2020;20(1). doi:10.1186/s12879-020-05536-z
   Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2015;62(4):e1–e50. doi:10.1093/cid/civ933
   PubMedGoogle Scholar
• Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(SUPPL.7):19–37. doi:10.1111/1469-0691.12039
   PubMed Web of Science ®Google Scholar
• Alothman AF, Al-Musawi T, Al-Abdely HM, et al. Clinical practice guidelines for the management of invasive Candida infections in adults in the Middle East region: expert panel recommendations. J Infect Public Health. 2014;7(1):6–19. doi:10.1016/j.jiph.2013.08.002
   PubMed Web of Science ®Google Scholar
• Nucci M, Colombo A. Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis. 2002;21(3):209–211. doi:10.1007/s10096-002-0697-1
   PubMed Web of Science ®Google Scholar
• Breda GL, Tuon FF, Meis JF, et al. Breakthrough candidemia after the introduction of broad spectrum antifungal agents: a 5-year retrospective study. Med Mycol. 2018;56(4):406–415. doi:10.1093/mmy/myx077
   PubMed Web of Science ®Google Scholar
• Cornely OA, Hoenigl M, Lass-Flörl C, et al. Defining breakthrough invasive fungal infection–Position paper of the mycoses study group education and research consortium and the European Confederation of medical mycology. Mycoses. 2019;62(9):716–729. doi:10.1111/myc.12960
   PubMed Web of Science ®Google Scholar
• Calculator.net. Sample size calculator; 2022. Available from: https://www.calculator.net. Accessed June 23, 2023.
   Google Scholar
• Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Biomerieux SA. Instrument User Manual VITEK® MS Clinical Use-EN; 2019. Available from: www.biomerieux.com. Accessed June 23, 2023.
   Google Scholar
• Instructions for use thermo scientific sensititre yeastone susceptibility plate’s 029-YEAST-ROW-IVD CID8962; 2015. Available from: www.trekds.com/techinfo. Accessed June 23, 2023.
   Google Scholar
• Procop GW; Clinical and Laboratory Standards Institute. Performance Standards for Antifungal Susceptibility Testing of Yeasts. Clinical and Laboratory Standards Institute; 2017.
   Google Scholar
• Alexander BD; Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Clinical and Laboratory Standards Institute; 2017.
   Google Scholar
• Procop GW; Clinical and Laboratory Standards Institute. Epidemiological Cutoff Values for Antifungal Susceptibility Testing. Clinical and Laboratory Standards Institute; 2017.
   Google Scholar
• EUCAST. European committee on antimicrobial susceptibility testing breakpoint tables for interpretation of mics for antifungal agents; 2020.
   Google Scholar
• EUCAST. General changes clinical breakpoints and ECOFFs for yeasts clinical breakpoints and ECOFFs for moulds clinical breakpoints and ECOFFs for dermatophytes 8 European committee on antimicrobial susceptibility testing. Available from: http://www.eucast.org. Accessed June 23, 2023.
   Google Scholar
• Lass-Flörl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses. 2009;52(3):197–205. doi:10.1111/j.1439-0507.2009.01691.x
   PubMed Web of Science ®Google Scholar
• Osoba AO, Amaw MDE, McAlear DE, Hussein BA. Candidemia and the susceptibility pattern of Candida isolates in blood. Saudi Med J. 2003;24(10):1060–1063.
   PubMed Web of Science ®Google Scholar
• Reboli AC. Editorial commentary: is the debate about treatment of Candida parapsilosis complex infections with echinocandins much ado about nothing? Clin Infect Dis. 2014;58(10):1422–1423. doi:10.1093/cid/ciu160
   PubMed Web of Science ®Google Scholar
• Lockhart’ SR, Joly S, Vargas K, Swails-Wengerl J, Engerl L, Solll DR. Natural defenses against Candida colonization breakdown in the oral cavities of the elderly. J Dent Res. 1999;78(4):857–868. doi:10.1177/00220345990780040601
   PubMed Web of Science ®Google Scholar
• Bouza E, Burillo A, Muñoz P, Guinea J, Marín M, Rodríguez-Créixems M. Mixed bloodstream infections involving bacteria and Candida spp. J Antimicrob Chemother. 2013;68(8):1881–1888. doi:10.1093/jac/dkt099
   PubMed Web of Science ®Google Scholar
• Antworth A, Collins CD, Kunapuli A, et al. Impact of an antimicrobial stewardship program comprehensive care bundle on management of candidemia. Pharmacotherapy. 2013;33(2):137–143. doi:10.1002/phar.1186
   PubMed Web of Science ®Google Scholar
• Lee RA, Zurko JC, Camins BC, et al. Impact of infectious disease consultation on clinical management and mortality in patients with candidemia. Clin Infect Dis. 2019;68(9):1585–1587. doi:10.1093/cid/ciy849
   PubMed Web of Science ®Google Scholar
• Yang F, Zhang L, Wakabayashi H, et al. Tolerance to caspofungin in Candida albicans is associated with at least three distinctive mechanisms that govern expression of FKS genes and cell wall remodeling. Antimicrob Agents Chemother. 2017;61(5). doi:10.1128/AAC.00071-17
   Web of Science ®Google Scholar
• Jenks JD, Cornely OA, Chen SCA, Thompson GR, Hoenigl M. Breakthrough invasive fungal infections: who is at risk? Mycoses. 2020;63(10):1021–1032. doi:10.1111/myc.13148
   PubMed Web of Science ®Google Scholar
• Khan Z, Ahmad S, Al-Sweih N, Joseph L, Alfouzan W, Asadzadeh M. Increasing prevalence, molecular characterization and antifungal drug susceptibility of serial Candida auris isolates in Kuwait. PLoS One. 2018;13(4). doi:10.1371/journal.pone.0195743
   Web of Science ®Google Scholar
• Aljindan R, Aleraky DM, Mahmoud N, et al. Drug resistance-associated mutations in erg11 of multidrug-resistant candida auris in a tertiary care hospital of eastern Saudi Arabia. J Fungus. 2021;7(1):1–9. doi:10.3390/jof7010018
   Google Scholar
• Alexander BD, Espinel-Ingroff A, Pemán J; Clinical and Laboratory Standards Institute. Performance standards for antifungal susceptibility testing of yeasts. Expert Rev Anti Infect Ther. 2009;7(1):107–119. doi:10.1586/14787210.7.1.107
   PubMedGoogle Scholar